Patents by Inventor Na-Gyong Lee
Na-Gyong Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220287970Abstract: A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed. Saponin exhibits a wide range of pharmacological and biological activities, such as anti-inflammatory activity, etc., including strong and effective immunological activity, and thus is effectively used medically and pharmaceutically, but has a disadvantage of causing hemolysis to red blood cells. Although saponin is generally used along with cholesterol, etc.Type: ApplicationFiled: May 28, 2021Publication date: September 15, 2022Inventors: Yang Je CHO, Na Gyong LEE, Kwangsung KIM, Shin Ae PARK, Sunyoung AHN
-
Patent number: 10918709Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.Type: GrantFiled: October 30, 2017Date of Patent: February 16, 2021Assignee: EYEGENE INC.Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Patent number: 10874733Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.Type: GrantFiled: October 30, 2017Date of Patent: December 29, 2020Assignee: EYEGENE INC.Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Publication number: 20190290749Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.Type: ApplicationFiled: October 30, 2017Publication date: September 26, 2019Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Publication number: 20190255171Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.Type: ApplicationFiled: October 30, 2017Publication date: August 22, 2019Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Patent number: 9572877Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: GrantFiled: December 17, 2011Date of Patent: February 21, 2017Assignee: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won II Yoo
-
Patent number: 9566323Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: GrantFiled: October 20, 2009Date of Patent: February 14, 2017Assignee: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Patent number: 8883987Abstract: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: GrantFiled: March 24, 2006Date of Patent: November 11, 2014Assignee: Eyegene Inc.Inventors: Bo Young Ahn, Yang Je Cho, Won Il Yoo, Sung Ho Lee, Hye Ran Park, Dong Hyun Lee, Na-Gyong Lee, Doo Sik Kim
-
Publication number: 20130273101Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 17, 2011Publication date: October 17, 2013Applicant: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
-
Publication number: 20120100169Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: ApplicationFiled: October 20, 2009Publication date: April 26, 2012Applicant: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Publication number: 20100112013Abstract: Disclosed is an adjuvant composition of the present invention including the oligodeoxynucleotides and the LPS-derived non-toxic polysaccharides as the major components.Type: ApplicationFiled: July 29, 2005Publication date: May 6, 2010Inventors: Na-Gyong Lee, Bo-Young Ahn, Won-II Yoo, Yang-Je Cho
-
Publication number: 20090285844Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: ApplicationFiled: March 30, 2009Publication date: November 19, 2009Inventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Rasappa Arumugham, Bradford W. Gibson
-
Patent number: 7510717Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: January 12, 2006Date of Patent: March 31, 2009Assignee: University of Iowa Research FoundationInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Rasappa Arumugham, Bradford W. Gibson
-
Patent number: 7507802Abstract: The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: GrantFiled: September 26, 2002Date of Patent: March 24, 2009Assignee: Eyegene, Inc.Inventors: Bo Young Ahn, Yang Je Cho, Won Il Yoo, Sung Ho Lee, Hye Ran Park, Dong Hyun Lee, Na-Gyong Lee, Doo Sik Kim
-
Patent number: 7226588Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: March 23, 2005Date of Patent: June 5, 2007Assignees: University of Iowa Research Foundation, The Regents of the University of CaliforniaInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Bradford W. Gibson
-
Publication number: 20070104736Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: ApplicationFiled: March 23, 2005Publication date: May 10, 2007Inventors: Michael Apicella, Melvin Sunshine, Na-Gyong Lee, Bradford Gibson
-
Publication number: 20070048331Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically. effective amount of the vaccine formulation.Type: ApplicationFiled: January 12, 2006Publication date: March 1, 2007Inventors: Michael Apicella, Melvin Sunshine, Na-Gyong Lee, Rasappa Arumugham, Bradford Gibson
-
Publication number: 20060166923Abstract: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: ApplicationFiled: March 24, 2006Publication date: July 27, 2006Inventors: Bo Young Ahn, Yang Je Cho, Won Il Yoo, Sung Ho Lee, Hye Ran Park, Dong Hyun Lee, Na-Gyong Lee, Doo Sik Kim
-
Patent number: 7005129Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: November 27, 1996Date of Patent: February 28, 2006Assignees: University of Iowa Research Foundation, The Regents of the University of CaliforniaInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Bradford W. Gibson, Rasappa Arumugham
-
Publication number: 20050163806Abstract: The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: ApplicationFiled: September 26, 2002Publication date: July 28, 2005Applicants: EyeGene Inc., Daewoong Life Science InstituteInventors: Bo Ahn, Yang Cho, Won Il Yoo, Sung Lee, Hye Park, Dong Lee, Na-Gyong Lee, Doo Kim